Journal of Vaccines & Vaccination

Fusion expression of the recombinant protective antigen of Bacillus anthracis in E.coli

International Conference & Exhibition on Vaccines & Vaccination

22-24 Nov 2011 Philadelphia Airport Marriott, USA

V. Bagheri, H. Motamedi and M. R. Seyfi abad Shapouri

Posters: J Vaccines Vaccin

Abstract:

Anthrax is a fatal infection caused by Bacillus anthracis . Protective antigen (PA) is one of the toxin components and essential component of the human anthrax vaccines. Th e current licensed human vaccines are produced in the United States (AVA) and United Kingdom. Th e current human vaccines have several limitations. Th ey can cause side eff ects and require multiple boosters to maintain immunity. Th erefore, a new generation of vaccines are required against anthrax.Th e objective of this study was to express recombinant PA for human vaccine studies and diagnosis of disease. Th e PA gene was cloned into the pMAL-c2X expression vector and transformed into E.coli DH5�±. Th e expression of recombinant fusion protein (rMBP-PA) was identifi ed by SDS-PAGE and Western blotting using anti-PA monoclonal antibody. Th e results showed that the PA gene was expressed as a fusion protein with maltose-binding protein (MBP). SDS-PAGE and Western blotting detected a protein band about 125 kDa, which was similar to rMBP-PA fusion protein. Anthrax is a health problem in developing countries and occurs among animals and humans.In this study we used the pMAL expression system for high expression of PA in E. coli . Th is expression system has several advantages (IPTG induction and one-step affi nity purifi cation process) and can be used for high level expression and large scale production of recombinant PA. We successfully expressed B.anthracis PA in the E.coli . Recombinant PA may be used for development of a new human recombinant anthrax vaccine that is safe, eff ective, and improved.

Biography :

Vahid Bagheri received his BSc in cellular and molecular biology at the age of 22 from Tarbiat Moallem university of Tehran, MSc in microbiology at the age of 24 from Shahid Chamran university of Ahvaz. His research interests are infectious diseases, vaccine development, and pharmaceutical biotechnology. His fi rst paper is published in asian paci fi c journal of tropical medicine (apjtm) in 2010.Currently he is applying for phd.